Small Molecule Drug Conjugate (SMDC) Development
Seprase (FAP)-targeted small molecule-drug conjugates (SMDCs) is another breakthrough in cancer therapy. These agents take advantage of high expression of seprase (FAP) on cancer-associated fibroblasts to facilitate drug delivery directly to tumor cells, thus maximizing therapeutic efficacy while minimizing off-target injury. At Alfa Cytology, we are ready to face the unique issues present in this dynamic field through comprehensive and innovative development services targeted toward seprase (FAP)-targeted SMDCs.
Introduction to Seprase (FAP)-Targeted Small Molecule Drug Conjugates (SMDCs)
Recently, the seprase (FAP) has emerged as a potential therapeutic target for cancer, given its high expression level on cancer-associated fibroblasts within the tumor microenvironment. seprase (FAP)-targeted small molecule-drug conjugates (SMDCs) utilize this unique protein to deliver cytotoxic agents directly to tumor cells, thus enhancing therapeutic efficacy and minimizing harm to adjacent normal tissues. With this novel approach, a major enhancement in targeted cancer therapies aims at improving patient outcomes.
Fig. 1 In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. (Bocci, M., et al. 2024)
Development of Seprase (FAP)-Targeted Small Molecule Drug Conjugates (SMDCs)
| Name | Drug Development Institute | Phase |
|---|---|---|
| 90Y-FAPI-04 | University Hospital Heidelberg | Phase I |
| 90Y-FAPI-46 | University Hospital Essen | Phase II |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
Alfa Cytology takes pride in having the ability to provide specialized services that can assist in the development of seprase (FAP)-targeted SMDCs. Our multidisciplinary team, made up of experts in pharmacology, medicinal chemistry, and drug formulation, is fully equipped to support you in drug developments. Our cutting-edge methods can bring your project forth from conception to clinic-ready while maintaining the highest industry standards.
Targeting Ligand Screening
Alfa Cytology specializes in the screening of such seprase (FAP)-targeting ligands, using state-of-the-art high-throughput methods. In seeking to identify specific antibodies and small molecules that bind optimally to seprase (FAP), we can design highly selective and efficacious SMDCs. Our experts easily perform such different selection tests on considerations of binding affinities, biological activities, and the potential for others.
Linker Design and Synthesis
Alfa Cytology carries out the design and synthesis of tailored linkers allowing targeted release of the therapeutic agent at seprase (FAP)-positive cells. The incorporation of cleavable or non-cleavable linkers means that SMDCs can be designed for retention of therapeutic potential and maximal activity at desired locations.
Selection of Payload
Various small molecule therapeutic agent selection services are present to provide payloads that are optimized towards any applications involving seprase (FAP) targeting. Using our added value through drug development skills, we guarantee that our payloads shall even be maximally effective in the clinic while being compatible with targeting delivery mechanisms.
Alfa Cytology is committed to offering exceptional services in the development of seprase (FAP)-targeted SMDCs in order to identify the most promising drug candidates. Should you require to learn more about our capabilities or collaboration, do not hesitate to contact us.
Reference
- Bocci, M., et al. In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment. Journal of controlled release : official journal of the Controlled Release Society. 2024, 367: 779-790.
For research use only.